Portal de Periódicos da CAPES

Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

2014; Oxford University Press; Volume: 1; Issue: 4 Linguagem: Inglês

10.1093/nop/npu021

2054-2585

Alba A. Brandes, Enrico Franceschi, Mario Ermani, Alicia Tosoni, Fiorenzo Albani, Roberta Depenni, Marina Faedi, Anna Pisanello, Girolamo Crisi, Benedetta Urbini, Claudio Dazzi, Luigi Cavanna, Claudia Mucciarini, Elena Pasini, Stefania Bartolini, Gianluca Marucci, Luca Morandi, Elena Zunarelli, Serenella Cerasoli, Giorgio Gardini, Giovanni Lanza, Enrico Maria Silini, Silvio Cavuto, Agostino Baruzzi, Agostino Baruzzi, Fiorenzo Albani, Fabio Calbucci, Roberto D’Alessandro, Roberto Michelucci, Alba A. Brandes, Vincenzo Eusebi, Samuele Ceruti, Enrico Fainardi, R Tamarozzi, Ermanno Emiliani, Michele Alessandro Cavallo, Enrico Franceschi, A. Tosoni, Michele Alessandro Cavallo, Francesco Fiorica, A. Valentini, Roberta Depenni, Claudia Mucciarini, Girolamo Crisi, Enrico Sasso, Claudia Biasini, Luigi Cavanna, Donata Guidetti, Norina Marcello, Anna Pisanello, Anna Maria Cremonini, G. Guiducci, Silvia de Pasqua, S. Testoni, R. Agati, G. Ambrosetto, A. Bacci, Elisa Baldin, A. Baldrati, Elisa Barbieri, Stefania Bartolini, E. Bellavista, Francesca Bisulli, Elena Bonora, Feisal Bunkheila, Valério Carelli, Michela Crisci, P. Dall'Occa, Dario de Biase, Salvatore Ferro, C. Franceschi, G. Frezza, V. Grasso, Matilde Leonardi, Gianluca Marucci, V. Mazzocchi, Luca Morandi, Barbara Mostacci, Giorgio Palandri, Elisa Pasini, Marco Pastore Trossello, Annalisa Pession, Moira Ragazzi, P. Riguzzi, Roberta Rinaldi, Silvia Rizzi, G Romeo, F. Spagnolli, Paolo Tinuper, C. Trocino, Serenella Cerasoli, Monia Dall’Agata, Marina Faedi, M. Frattarelli, G. Gentili, A. Giovannini, P. Iorio, U. Pasquini, Giuseppe Galletti, Carlo Guidi, Walter Neri, Alberto Patuelli, Silvia Strumia, Mario Casmiro, Alessandro Gamboni, F. Rasi, Giuseppe Cruciani, P. Cenni, Claudio Dazzi, AR. Guidi, F. Zumaglini, Alberto Amadori, Elena Pasini, Mary Pasquinelli, Ernesto Pasquini, A. Polselli, Alessandro Ravasio, Beatrice Viti, M. Sintini, Alessandra Ariatti, Federica Bertolini, Guido Bigliardi, P. Carpeggiani, Francesca Cavalleri, Stefano Meletti, Paolo Nichelli, Elisa Pettorelli, Giovanni Pinna, Elena Zunarelli, Fabrizio Artioli, Ilaria Bernardini, Matías Costa, Gabriele Greco, R. Guerzoni, C. Stucchi, Corrado Iaccarino, Romana Rizzi, Giulio Zuccoli, P. Api, F. Cartei, Elisa Fallica, Enrico Granieri, Francesco Latini, G. Lelli, C Monetti, Vania Ramponi, Andrea Saletti, R. Schivalocchi, Silva Seraceni, Maria Rosaria Tola, Benedetta Urbini, Carlotta Giorgi, E. Montanari, Davide Cerasti, Pellegrino Crafa, Isabella Dascola, Irene Florindo, S. Mazza, Franco Servadei, EM. Silini, P Torelli, Paolo Immovilli, Nicola Morelli, C. Vanzo,

Meningioma and schwannoma management

Abstract Background As yet, no population-based prospective studies have been conducted to investigate the incidence and clinical outcome of glioblastoma (GBM) or the diffusion and impact of the current standard therapeutic approach in newly diagnosed patients younger than aged 70 years. Methods Data on all new cases of primary brain tumors observed from January 1, 2009, to December 31, 2010, in adults residing within the Emilia-Romagna region were recorded in a prospective registry in the Project of Emilia Romagna on Neuro-Oncology (PERNO). Based on the data from this registry, a prospective evaluation was made of the treatment efficacy and outcome in GBM patients. Results Two hundred sixty-seven GBM patients (median age, 64 y; range, 29–84 y) were enrolled. The median overall survival (OS) was 10.7 months (95% CI, 9.2–12.4). The 139 patients ≤aged 70 years who were given standard temozolomide treatment concomitant with and adjuvant to radiotherapy had a median OS of 16.4 months (95% CI, 14.0–18.5). With multivariate analysis, OS correlated significantly with KPS (HR = 0.458; 95% CI, 0.248–0.847; P = .0127), MGMT methylation status (HR = 0.612; 95% CI, 0.388–0.966; P = .0350), and treatment received in a high versus low-volume center (HR = 0.56; 95% CI, 0.328–0.986; P = .0446). Conclusions The median OS following standard temozolomide treatment concurrent with and adjuvant to radiotherapy given to (72.8% of) patients aged ≤70 years is consistent with findings reported from randomized phase III trials. The volume and expertise of the treatment center should be further investigated as a prognostic factor.